AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

AbbVie ABBV stock has declined 3.2% in a month. Shares of this large drugmaker dipped recently after it denied takeover talks with Redwood City, CA-based cancer biotech, Revolution Medicines RVMD.

AbbVie Inc. (NYSE:ABBV) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, Berenberg raised ...

AbbVie’s solid stock performance is driven by rising investor optimism as the company has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, which once generated ...

AbbVie's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Learn more about ABBV stock here.

AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in. On January 14, 2026, Reuters reported ...

AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median. ABBV consistently delivers double beats, maintains robust FCF margins, and is ...

ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...

These stocks sport dividend yields ranging from 2.9% to 5.5%.